-
-
-
公开(公告)号：KR1020040066300A
公开(公告)日：2004-07-27
申请号：KR1020030003320
申请日：2003-01-17
IPC: A61K9/107
CPC classification number: A61K9/107 , A61K31/337 , A61K45/06 , A61K47/24 , A61K47/44 , A61K49/0438
Abstract: PURPOSE: A paclitaxel mixed composition, its water-in-oil type emulsion formulation for chemoembolization and a preparation method thereof are provided, thereby improving stability of the emulsion formulation, and applying the paclitaxel to artery chemoembolization. CONSTITUTION: The paclitaxel mixed composition comprises 50 to 98.9%(v/v) of oily contrast media containing 0.01 to 1%(w/v) of paclitaxel, and 0.1 to 50%(v/v) of water-soluble contrast media. The water-in-oil type emulsion formulation for chemoembolization comprises 50 to 98.9%(v/v) of oily contrast media, 0.1 to 50%(v/v) of water-soluble contrast media, and 0.01 to 1%(w/v) of paclitaxel, wherein the oily contrast media are iodized oil containing 30 to 50% of iodine content selected from iodized poppy seed oil, ethiodol and iodized soybean oil; the water-soluble contrast media are selected from Metrizamide, Diatrizoate, Ioxaglate, Iopentol, Iopamidol, Iomeprol, Iotrolan, Iohexol, Ioversol, Ioxilan, Iopromide, Iodixanol or Iobitridol.
Abstract translation: 目的：提供紫杉醇混合组合物，其用于化学栓塞的油包水型乳液制剂及其制备方法，从而提高乳液制剂的稳定性，并将紫杉醇应用于动脉化学栓塞。 构成：紫杉醇混合组合物包含含有0.01至1％（w / v）紫杉醇和0.1至50％（v / v）水溶性造影剂的50至98.9％（v / v）油性造影剂。 用于化学栓塞的油包水型乳液制剂包含50至98.9％（v / v）的油性造影剂，0.1至50％（v / v）的水溶性造影剂，和0.01至1％（w / v）的紫杉醇，其中所述油性造影剂是含有选自碘化罂粟籽油，碘化碘和碘化大豆油中的30-50％碘含量的碘化油; 水溶性造影剂选自Metrizamide，Diatrizoate，Ioxaglate，Iopentol，Iopamidol，Iomeprol，Iotrolan，Iohexol，Ioversol，Ioxilan，Iopromide，Iodixanol或Iobitridol。
-
公开(公告)号：KR100375422B1
公开(公告)日：2003-03-10
申请号：KR1019990060034
申请日：1999-12-21
Applicant: 한국과학기술연구원
IPC: C12N1/00
CPC classification number: C08J9/28 , C08B37/003 , C08J2201/0484 , C08J2305/08 , C08L5/08 , C12N5/0075 , C12N2533/72
Abstract: The present invention relates to macroporous chitosan beads having 5-200 mum in size of relatively large and uniform pores that are distributed from surface to core region, and a preparation method thereof compring the following steps; by dropping chitosan solution, aqueous chitosan solution or their mixture into the low-temperature of organic solvent or liquid nitrogen; and by regulating pore size by phase separation method via temperature difference. The macroporous chitosan beads of the present invention make cell culture more efficient than the previous substrate, since cell can attach to them efficiently due to their large surface area, it is easy for cell to be injected into them and cell attached to them can exist longer due to their three-dimensional structure, therefore they can be used for a study about production of protein, abtibiotics, anticancer agent, polysaccharide, physiologically active agent, animal hormone, or plant hormone as well as a study about substitution of metabolic organs, cartilage or bone.
Abstract translation: 本发明涉及一种大孔径壳聚糖珠粒及其制备方法，所述大孔隙大小为5-200μm，具有较大且均匀的从表面到中心区域的孔隙，其制备方法包括以下步骤： 将壳聚糖溶液，壳聚糖水溶液或其混合物滴入低温有机溶剂或液氮中; 并通过温度差通过相分离法调节孔径。 本发明的大孔脱乙酰壳多糖珠粒使细胞培养比先前的基质更有效，因为细胞由于它们的大表面积而可以有效地附着到它们上，细胞很容易注入它们并且细胞附着在它们上的时间可以更长 由于它们的三维结构，因此它们可以用于研究蛋白质，抗生素，抗癌剂，多糖，生理活性剂，动物激素或植物激素的产生，以及关于代谢器官，软骨替代的研究 或骨头。
-
公开(公告)号：KR1020030015926A
公开(公告)日：2003-02-26
申请号：KR1020010049772
申请日：2001-08-18
Applicant: 한국과학기술연구원 , 주식회사 스마트세이프존
IPC: A61K47/48
CPC classification number: A61K31/704 , A61K47/61 , A61K47/6907 , A61K47/50
Abstract: PURPOSE: Provided is a complex capable of forming a spherical self-aggregate similar to a micelle in an aqueous system by amphiphilicity containing both a hydrophobic group of an anticancer agent and a hydrophilic group of chitosan, thereby allowing a sustained release of the drug and increasing selectivity to cancer tissue. CONSTITUTION: The anticancer agent-chitosan complex having a diameter of 10 to 800nm comprises 1 to 70% by weight of a hydrophobic anticancer agent and hydrophilic chitosan having an average molecular weight of 10¬3 to 10¬6 and additionally a linker which is decomposed in an acid. The hydrophobic anticancer agent is selected from the group consisting of adriamycin, taxol, cis-platin, mitomycin-C, daunomycin and 5-fluorouracil.
Abstract translation: 目的：提供一种复合物，其能够通过包含抗癌剂的疏水基团和壳聚糖的亲水基团的两亲性形成与水性体系中的胶束相似的球形自聚集体，从而允许药物的持续释放和增加 对癌组织的选择性。 构成：直径为10〜800nm的抗癌剂 - 壳聚糖复合物包含1〜70重量％的疏水性抗癌剂和平均分子量为10〜10〜16的亲水性壳聚糖，另外还有分解的接头 在酸中。 疏水性抗癌剂选自阿霉素，紫杉醇，顺铂，丝裂霉素-C，道诺霉素和5-氟尿嘧啶。
-
Patent Agency Ranking
公开(公告)号：KR1020020005563A
公开(公告)日：2002-01-17
申请号：KR1020017001096
申请日：1999-08-19
Applicant: 한국과학기술연구원
IPC: A61K9/50
CPC classification number: A61K47/36 , A61K9/1652 , A61K39/092
Abstract: PURPOSE: Provided are vaccine compositions for oral administration consisting of a protein antigen encapsulated in biodegradable alginate microspheres by the diffusion-controlled interfacial gelation technique which produces microspheres having less than 5μm of diameter, and to preparation process thereof. CONSTITUTION: The process for preparing the vaccine composition comprises the steps of: i) mixing aliquot of a protein antigen or a protein antigen including immune adjuvant with an alginate aqueous solution; ii) homogenizing by adding a mixture of the alginate and a protein antigen of step i) to n-octanol containing an emulsifier; iii) spraying n-octanol solution containing CaCl2 into the emulsion while stirring the whole emulsion slowly; iv) adding additional CaCl2 solution to saturate the emulsion, and curing microspheres; v) dehydrating microspheres by addition of dehydrating solvent; vi) collecting the microspheres on membrane filters and washing with alcohol, and then drying in vacuo.
Abstract translation: 目的：提供用于口服给药的疫苗组合物，其通过扩散控制的界面凝胶化技术包封在可生物降解的藻酸盐微球中的蛋白质抗原，其产生具有小于5μm直径的微球体及其制备方法。 构成：制备疫苗组合物的方法包括以下步骤：i）将蛋白质抗原或包含免疫佐剂的蛋白质抗原的等分试样与藻酸盐水溶液混合; ii）通过将步骤i）的藻酸盐和蛋白质抗原的混合物加入含有乳化剂的正辛醇进行均化; iii）将缓慢地搅拌整个乳液的含有CaCl 2的正辛醇溶液喷雾到乳液中; iv）加入另外的CaCl 2溶液使乳液饱和并固化微球; v）通过加入脱水溶剂脱水微球; vi）在膜过滤器上收集微球并用醇洗涤，然后真空干燥。
-
公开(公告)号：KR1020000012106A
公开(公告)日：2000-02-25
申请号：KR1019990031339
申请日：1999-07-30
Applicant: 한국과학기술연구원
IPC: A61K9/107
CPC classification number: A61K9/107 , A61K31/196 , A61K38/13 , A61K47/10 , A61K47/24 , A61K47/44 , A61K47/542 , A61K48/00
Abstract: PURPOSE: A B-triglyceride type fat emulsifier and triglyceride or ethyl stearate type lipid corpuscle capable of transmitting an inductor DNA and biological activation medicine is provided. CONSTITUTION: The lipid corpuscle is composed of more than one kind of the lipid corpuscle material 2 to 30 % which is selected among triglyceride or ethyl stearate having 12 to 18 carbon atoms; more than one kind of an emulsifier 0.01 to 20 % which includes a cat ion surface active agent; water taking up the rest. The lipid corpuscle can keep a stable state in a test tube as well as a living body and efficiently transmit an inductor such as DNA, a physiological active material and medicine to the targeted cell.
Abstract translation: 目的：提供能够传递电感DNA和生物活化药物的B-甘油三酯型脂肪乳化剂和甘油三酯或硬脂酸乙酯脂质小体。 构成：脂质体由多种脂质体2〜30％组成，选自甘油三酯或碳原子数12〜18的硬脂酸乙酯; 一种以上0.01〜20％的乳化剂，其含有猫离子表面活性剂; 水占据休息。 脂质体可以在试管和活体中保持稳定状态，并有效地将诸如DNA，生理活性物质和药物的感应器传输到靶细胞。
-
-
公开(公告)号：KR100131058B1
公开(公告)日：1998-04-11
申请号：KR1019930026559
申请日：1993-12-06
Applicant: 한국과학기술연구원
IPC: C08B37/10
Abstract: Sulfonated polyethyleneoxide derivs.(i), useful as an anticoagulating agent are prepd. by combining one or both end group of polyethyleneoxide derivs. with sulfonic acid group. Polethyleneoxide has a m.w. of 100-20,000. In formula R1=selected group from COOH,SO3H,SO3Na, R2=selected group from SO3H, SO3Na.
Abstract translation: 磺化聚环氧乙烷衍生物（i）可用作抗凝剂。 通过组合一个或两个端基的聚环氧乙烷衍生物。 与磺酸基团。 环氧丙烷具有m.w. 100-20,000。 式R 1 =选自COOH，SO 3 H，SO 3 Na，R 2 =选自SO 3 H，SO 3 Na的基团。
-
-
-
-
-
-
-
-
-
Search Results
70
records
(took 0.029 seconds)
